ProPhase Labs, Inc. Short-term Debt
ProPhase Labs, Inc. (PRPH) had Short-term Debt of $2.45 million as of 2025-03-31, per its 10-Q filed 2025-05-20.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Debt, Current
us-gaap:ShortTermBorrowings · last filed 2025-05-20
- 2025-03-31: Short-term Debt $2.45M.
- 2024-12-31: Short-term Debt $3.21M.
- 2024-09-30: Short-term Debt $2.67M.
- 2024-06-30: Short-term Debt $3.26M.
| Period end | Short-term Debt |
|---|---|
| 2025-03-31 | $2.45M 10-Q · filed 2025-05-20 |
| 2024-12-31 | $3.21M 10-Q · filed 2025-05-20 |
| 2024-09-30 | $2.67M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $3.26M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $2.38M 10-Q · filed 2024-05-10 |
| 2023-12-31 | $0.00 10-K · filed 2025-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |